BioMarin Pharmaceutical | BMRN - Fremdkapital

Aktienkurs
54.53
Täglich Wechseln
-1.77 -3.14%
Monatlich
-9.60%
Jährlich
-4.03%
Q2 Prognose
53.04




Fremdkapital Veränderung Datum
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Amgen USD 50B 2.43B 2025-12
Bayer EUR 31.83B 877M 2025-12
Biogen USD 6.29B 1.4M 2025-09
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Gilead Sciences USD 22.14B 5M 2025-09
Incyte USD 30.2M 5.17M 2025-12
Insmed USD 540.96M 1.24M 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
Moderna USD 610M 584M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
PTC Therapeutics USD 2.03B 193.22M 2025-12
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Roche Holding CHF 27.43B 966M 2025-12
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 15.72B 150.06M 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
United Therapeutics USD 100M 100M 2024-06
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03